NCT00181584View on ClinicalTrials.gov

Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

February 28, 2006

Conditions
Bone LossProstate Cancer
Interventions
DRUG

Zoledronic acid

Given intravenously once.

OTHER

Placebo

Given intravenously once.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

lead

Massachusetts General Hospital

OTHER

NCT00181584 - Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer | Biotech Hunter | Biotech Hunter